| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | Is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma. Rapid Review |
| Assessment Process | |
| Rapid review commissioned | 28/05/2015 |
| Rapid review completed | 16/07/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 30/10/2015 |
| NCPE assessment completed | 18/03/2016 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.